ストックスクリーナーアプリを入手
22.59
6.03%
1.2866
前日終値:
$21.30
開ける：
$21.3
24時間の取引高:
652.99K
Relative Volume:
0.66
時価総額：
$1.38B
収益：
-
当期純損益:
$-129.61M
株価収益率:
-7.5614
EPS:
-2.9871
ネットキャッシュフロー:
$-116.59M
1週間 パフォーマンス:
+1.64%
1か月 パフォーマンス:
+33.32%
6か月 パフォーマンス:
+71.29%
1年 パフォーマンス:
+116.13%
1日の値動き範囲:
$21.17
$22.69
1週間の範囲:
$20.20
$23.12
52週間の値動き範囲:
$6.67
$28.00
Jade Biosciences Inc Stock (JBIO) Company Profile
Compare JBIO vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
JBIO
Jade Biosciences Inc
|
22.62 | 1.30B | 0 | -129.61M | -116.59M | -2.9871 |
VRTX
Vertex Pharmaceuticals Inc
|
522.15 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
673.64 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
917.18 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
320.58 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.72 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Jade Biosciences Inc Stock (JBIO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-07 | 開始されました | H.C. Wainwright | Buy |
| 2025-10-09 | 開始されました | BTIG Research | Buy |
| 2025-07-14 | 開始されました | Jefferies | Buy |
| 2025-06-16 | アップグレード | Guggenheim | Neutral → Buy |
| 2025-05-07 | 開始されました | Wedbush | Outperform |
| 2025-05-05 | 開始されました | Stifel | Buy |
| 2025-05-02 | 開始されました | TD Cowen | Buy |
| 2024-06-18 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2024-06-18 | ダウングレード | TD Cowen | Buy → Hold |
| 2024-06-18 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2024-06-17 | ダウングレード | BTIG Research | Buy → Neutral |
| 2024-06-17 | ダウングレード | Guggenheim | Buy → Neutral |
| 2024-06-17 | ダウングレード | Wedbush | Outperform → Neutral |
| 2024-03-25 | 再開されました | Jefferies | Buy |
| 2023-12-08 | 開始されました | Wells Fargo | Equal Weight |
| 2023-03-01 | 開始されました | Guggenheim | Buy |
| 2022-12-06 | アップグレード | BTIG Research | Neutral → Buy |
| 2022-09-19 | 再開されました | Wedbush | Outperform |
| 2022-08-16 | ダウングレード | BTIG Research | Buy → Neutral |
| 2022-02-11 | 開始されました | BTIG Research | Buy |
| 2021-07-26 | 開始されました | Cowen | Outperform |
| 2021-07-26 | 開始されました | Evercore ISI | Outperform |
| 2021-07-26 | 開始されました | Jefferies | Buy |
| 2021-07-26 | 開始されました | Wedbush | Outperform |
すべてを表示
Jade Biosciences Inc (JBIO) 最新ニュース
JBIOJade Biosciences Inc Options - Finviz
Jade Biosciences (JBIO) Joins Growth Indexes, Is The Stock Still Undervalued? - Sahm
Jade Biosciences Company Profile & Introduction - Moomoo
Jade Biosciences to Receive up to $22 Million as Part of Licensing Deal With Paragon Therapeutics - marketscreener.com
Jade BiosciencesEnters Exclusive Worldwide License Agreement With Paragon TherapeuticsSEC Filing - TradingView
Jade Biosciences Secures Exclusive Antibody License Agreement - TipRanks
Jade Biosciences Secures Global Exclusive Antibody License From Paragon Therapeutics With Milestones Up to $22M - TradingView
Is Jade Biosciences, Inc. (JBIO) Stock a Rising Biotech Opportunity in the $20B IgA Nephropathy Market? - Yahoo Finance
Jade Biosciences, Inc.(NasdaqCM:JBIO) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Jade Biosciences, Inc.(NasdaqCM: JBIO) added to Russell 2000 Growth Benchmark - marketscreener.com
Jade Biosciences, Inc.(NasdaqCM:JBIO) dropped from Russell Small Cap Comp Value Benchmark - marketscreener.com
Jade Biosciences, Inc.(NasdaqCM: JBIO) added to Russell 3000E Growth Benchmark - marketscreener.com
Jade Biosciences, Inc.(NasdaqCM: JBIO) dropped from Russell 3000 Value Benchmark - marketscreener.com
Jade Biosciences, Inc.(NasdaqCM: JBIO) dropped from Russell 2500 Value Benchmark - marketscreener.com
Jade Biosciences, Inc.(NasdaqCM:JBIO) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
5 Best Biotech Stocks to Buy According to Analysts - Insider Monkey
Form 4 Jade Biosciences Inc For: 26 June By Investing.com - Investing.com South Africa
Jade Biosciences (JBIO) director receives 47,675 stock options at $21.81 strike - Stock Titan
Jade Biosciences (JBIO) director Mark Eisner files initial Form 3 - Stock Titan
Form 3Initial statement of beneficial ownership of securities - ADVFN
Jade Biosciences appoints Mark Eisner to board of directors By Investing.com - Investing.com South Africa
Jade Biosciences appoints Mark Eisner to board of directors - Investing.com
Jade Biosciences Adds Veteran Biopharma Leader to Board - TipRanks
Jade Biosciences Appoints Dr. Mark Eisner to Board, Strengthening Leadership for Autoimmune Therapy Pipeline - Minichart
Jade Biosciences appoints Mark Eisner to its Board and Nominating & Corporate Governance Committee - TradingView
Immunology leader Mark Eisner joins Jade Biosciences (NASDAQ: JBIO) board - Stock Titan
Jade Biosciences Announces Appointment of Mark Eisner, M.D., M.P.H., to Board of Directors - The Manila Times
Jade Biosciences, Inc. Actuals & Estimates (NASDAQ:JBIO) - TradingView
JBIO Forecast — Price Target — Prediction for 2027 - TradingView
Jade Biosciences, Inc.(NasdaqCM: JBIO) added to S&P Biotechnology Select Industry Index - marketscreener.com
Jade Biosciences Ord Shs (JBIO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Jade Biosciences (JBIO) Surges 5.6% as Biotech Momentum BuildsAAII Neutral - dars.gov.et
UBS Maintains Jade Biosciences(JBIO.US) With Buy Rating, Maintains Target Price $45 - Moomoo
UBS Initiates Jade Biosciences(JBIO.US) With Buy Rating, Announces Target Price $45 - Moomoo
UBS Initiates Jade Biosciences at Buy With $45 Price Target - Moomoo
UBS initiates Jade Biosciences stock at Buy on IgAN drug potential - Investing.com Canada
JBIO Initiated Coverage by UBS -- Price Target Set at $45.00 - GuruFocus
Jade Biosciences Inc. (JBIO) Q1 2026 Earnings: Loss Wider Than Expected as Pre-Revenue Biotech Prioritizes Pipeline - newsline.com
Jade Biosciences Shareholders Approve Governance and Audit Measures - TipRanks
[Form 4] Jade Biosciences, Inc. Insider Trading Activity - Stock Titan
Jade Biosciences (JBIO) director granted 34,843 stock options at $15.22 strike price - Stock Titan
Jade Biosciences (JBIO) awards director 34,843 stock options at $15.22 - Stock Titan
Jade Biosciences (JBIO) director Erin Lavelle receives 34,843-share option grant - Stock Titan
Director Kiselak receives 34,843-share Jade Biosciences (JBIO) stock option grant - Stock Titan
Jade Biosciences (NASDAQ: JBIO) holders back charter and bylaw changes - Stock Titan
Fairmount funds lock up 19.99% stake in Jade Biosciences (JBIO) - Stock Titan
Jade Biosciences' JADE101 delivers deep IgA cuts, clearing path for kidney trials - MSN
JBIO Q1 2026 Earnings: Miss on EPS as Pre-Revenue Biotech Faces Investor SkepticismEarnings Trend Analysis - newsline.com
Jade Biosciences Completes Public Offering of 11.5 Million Shares, Raising $172.5 Million for Autoimmune Disease Therapies - Moomoo
Jade Biosciences closes $172.5m public offering - scanx.trade
Jade Biosciences prices $150M public offering of common stock at $15/share - MSN
Jade Biosciences Inc (JBIO) 財務データ
収益
当期純利益
現金流量
EPS
1.21%
3.14%
大文字化:
|
ボリューム (24 時間):